论文部分内容阅读
骨膦化学成份为氯甲双磷酸二钠,尿双磷酸盐类药物,有胶囊及静滴输注液两种剂型,具有强效抑制破骨细胞的活性,对骨组织有选择性吸附作用,国外文献已有广泛报导。 我科于1993年9月至1995年8月,应用芬兰利拉斯药厂生产的骨膦治疗骨转移癌及多发性骨髓瘤共22例报告如下: 1 一般资料 22例病人中男性14例、女性8例,所选择病人均有原发肿瘤,经病理学确诊并有X线片,骨扫描有转移的特征,所有病例,于一个月内均未作化疗及放疗。癌症病种及例数见表1。
The chemical composition of bone phosphine is disodium chloride disodium bisphosphate, urinary bisphosphonates, capsules and intravenous infusion fluids. It has strong inhibitory activity against osteoclasts and selective adsorption of bone tissue. Foreign literature has been widely reported. In our department from September 1993 to August 1995, a total of 22 cases of bone metastatic carcinoma and multiple myeloma treated with bone phosphine produced by the Finnish Lilas pharmaceutical company were reported as follows: 1 General information Among the 22 patients, 14 were male. In 8 female patients, all of the selected patients had primary tumors, which were diagnosed by pathology and had X-ray films. Bone scans had the characteristics of metastasis. All the patients had no chemotherapy or radiotherapy within one month. The number of cancer diseases and their cases are shown in Table 1.